MedTrace Logo

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

NCT07584954 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-13

No results posted yet for this study

Summary

This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

Conditions

  • Solid Tumor Cancer
  • Solid Tumor Cancer Treatment With Immunotherapy

Interventions

DRUG

IUAb190708, a cytotoxic antibody

a novel cytotoxic anti-PD-L1 antibody

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Anyang Tumor Hospital

    collaborator OTHER

  • Jun Zhou

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-18
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07584954 on ClinicalTrials.gov